Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 8/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3010245 | 0.98 | SMN1; SMN2 (0.52) | SMN1; SMN2MAPTNPC1RAB9ATP53 | |
| SCHEMBL7841197 | 0.96 | SMN1; SMN2 (0.47) | SMN1; SMN2MAPTNPC1RAB9ATP53 | |
| SCHEMBL8589909 | 0.93 | EPHX1 (0.56) | SMN1; SMN2MAPTNPC1RAB9ATP53 | |
| SCHEMBL8590406 | 0.92 | EPHX1 (0.54) | SMN1; SMN2MAPTNPC1RAB9ATP53 | |
| SCHEMBL7194159 | 0.86 | EPHX1 (0.59) | SMN1; SMN2EPHX1ACHEGAA | |
| SCHEMBL28783627 | 0.85 | GNAI3 (0.55) | SMN1; SMN2MAPTNPC1RAB9ATP53 | |
| SCHEMBL7750794 | 0.84 | EPHX1 (0.46) | SMN1; SMN2MAPTNPC1RAB9ATP53 | |
| SCHEMBL6381523 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPTNPC1RAB9ATP53 | |
| SCHEMBL7009651 | 0.82 | EPHX1 (0.40) | SMN1; SMN2MAPTNPC1RAB9ATP53 | |
| SCHEMBL6582896 | 0.82 | MAPT (0.47) | SMN1; SMN2MAPTNPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4712384-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| EP-1601674-A2 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO 4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-07 | — | — | EP | claimed |
| WO-2004022558-A2 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | claimed |
| US-11739070-B2 | C5A receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2023-08-29 | — | — | US | disclosed |
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20100204187-A1 | Purine Derivatives | PALAU PHARMA, S.A. (ES) | 2010-08-12 | — | — | US | disclosed |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| EP-1802590-A1 | SUBSTITUTED N-ALKYLPYRIMIDINONES | Pharmacia & Upjohn Company LLC (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040666-A1 | SUBSTITUTED N-ALKYLPYRIMIDINONES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1601674-A2 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO 4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-07 | — | — | EP | disclosed |
| EP-1460061-A1 | PROCESS FOR PRODUCING 1-ALKOXYCARBONYL NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004037800-A1 | ARYLOXYALKYLAMINE DERIVATES AS H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004022558-A2 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | disclosed |
| WO-1999040882-A2 | STEREOSELECTIVE Tc-99m LIGANDS | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1999-08-19 | — | — | WO | disclosed |
| EP-0757675-A1 | NOVEL QUINOLONE 5-(N-HETEROSUBSTITUTED AMINO) ANTIMICROBIALS | THE PROCTER & GAMBLE COMPANY (US) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995029894-A1 | NOVEL QUINOLONE 5-(N-HETEROSUBSTITUTED AMINO) ANTIMICROBIALS | THE PROCTER & GAMBLE COMPANY (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0527889-A4 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LAB (US) | 1994-08-10 | — | — | EP | disclosed |
| EP-0527889-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1993-02-24 | — | — | EP | disclosed |
| WO-1991016894-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | SMN1; SMN2 4587/4885MAPT 4202/4885NPC1 4526/4885 |
| US-20100204187-A1 | Purine Derivatives | JAK3, JAK1, JAK2 | SMN1; SMN2 3941/4885MAPT 4689/4885NPC1 3856/4885 |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | SMN1; SMN2 4587/4885MAPT 4202/4885NPC1 4526/4885 |
| US-11739070-B2 | C5A receptor modulators | C5AR1, C3AR1, C5AR2 | SMN1; SMN2 4661/4885MAPT 4529/4885NPC1 2424/4885 |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH2, HRH3 | SMN1; SMN2 4740/4885MAPT 2488/4885NPC1 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.